Announcements
Expression of concern regarding paper by Park et al, published on 25 June 2015: “Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015”, Euro Surveill. 2015;20(25):pii=21169. It has been brought to our attention that some of the authors may not have been informed about the content of the above paper. There is a lack of clarity regarding rights to use the data. The editorial team are investigating what action needs to be taken.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 6 Article 5
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 21, Issue 6, 11 February 2016
News
Eurosurveillance editorial team: European Commission Horizon 2020 programme call for vaccine development research into malaria and neglected infectious diseases, including Zika virus

+ Author affiliations


Citation style for this article: Eurosurveillance editorial team. European Commission Horizon 2020 programme call for vaccine development research into malaria and neglected infectious diseases, including Zika virus. Euro Surveill. 2016;21(6):pii=30132. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.6.30132


On 29 January 2016, the European Union (EU) Commissioner for Research, Science and Innovation, Carlos Moedas, informed that the EU would make available an additional EUR 10 million for urgent research on the Zika virus in response to the signals of an association between Zika virus infections and congenital abnormalities, including microcephaly [1]. This is in addition to EUR 40 million earmarked for research on vaccine development for malaria and neglected diseases, which includes the Zika virus, in the ‘Call - Personalised Medicine’ under the EU Horizon 2020 Work Programme 2016—2017 on health, demographic change and well-being [2]. The deadline for this call, is 13 April 2016 [2]. Its scope is to address bottlenecks in the discovery, preclinical and early clinical development of new vaccine candidates (antigens/adjuvants) for malaria and or neglected infectious diseases. Neglected infectious diseases for the scope of the call are, in addition to the 17 neglected tropical diseases prioritised by the World Health Organization [3] neglected viral emerging epidemic diseases, such as Zika virus disease, and childhood diarrhoeal diseases [2].

The expected impact of the call is:

  • • Proposals should deliver new vaccine candidates or move existing ones along the vaccine candidate pipeline to end by 2030 the epidemics of malaria and neglected tropical disease.

  • • To provide a reduction in the cost associated with late stage vaccine failure, increase the number of other vaccine candidates which can be tested with the same resources, and therefore increase the chance of discovery of an effective vaccine.

  • • If appropriate within the context of the European and Developing Countries Clinical Trials Partnership, increase the number and quality of vaccine candidates for malaria and neglected infectious diseases available to proceed into further development and clinical testing,

The additional EUR 10 million for research infrastructures is aimed at contributing to the control of vector-borne diseases under the call ‘Integrating Activities for Advanced Communities’ [4]. The deadline for the call is 30 March 2016.



References

  1. European Commission. The Commissioners Carlos Moedas. European Commission urges support for urgent Zika research. Available from: https://ec.europa.eu/commission/2014-2019/moedas/blog/european-commission-urges-support-urgent-zika-research_en

  2. European Commission. Horizon 2020 Work Programme 2016 - 2017. Health, demographic change and well-being. European Commission Decision C (2015)6776 of 13 October 2015.Off J Eur Union C. 2015;399:1. Available from: http://ec.europa.eu/research/participants/data/ref/h2020/wp/2016_2017/main/h2020-wp1617-health_en.pdf

  3. World Health Organization (WHO). Neglected tropical diseases. Geneva: WHO; 2016. Available from: http://www.who.int/neglected_diseases/diseases/en/

  4. European Commission. Horizon 2020 Work Programme 2016 - 2017. European Research Infrastructures (including e-Infrastructures). European Commission Decision C (2015)6776 of 13 October 2015.Off J Eur Union C. 2015;399:1. Available from: http://ec.europa.eu/research/participants/data/ref/h2020/wp/2016_2017/main/h2020-wp1617-infrastructures_en.pdf



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.